FY2024 EPS Estimate for Journey Medical Lowered by Analyst

Journey Medical Co. (NASDAQ:DERM) – Stock analysts at Roth Capital decreased their FY2024 earnings estimates for shares of Journey Medical in a research report issued to clients and investors on Monday, November 18th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share of ($1.00) for the year, down from their prior estimate of ($0.93). The consensus estimate for Journey Medical’s current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.09 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.15 EPS.

DERM has been the subject of a number of other research reports. Rodman & Renshaw started coverage on Journey Medical in a report on Thursday, August 22nd. They issued a “buy” rating and a $9.00 price target for the company. Lake Street Capital began coverage on Journey Medical in a research report on Friday, September 6th. They issued a “buy” rating and a $9.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Journey Medical currently has a consensus rating of “Buy” and a consensus price target of $9.38.

Journey Medical Stock Performance

NASDAQ:DERM opened at $5.37 on Thursday. The firm has a 50-day moving average of $5.64 and a two-hundred day moving average of $5.09. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. The stock has a market cap of $112.18 million, a P/E ratio of -5.84 and a beta of 0.92. Journey Medical has a 1-year low of $2.85 and a 1-year high of $8.11.

Institutional Trading of Journey Medical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nwam LLC acquired a new position in shares of Journey Medical in the 3rd quarter worth approximately $59,000. TMD Wealth Management LLC bought a new position in Journey Medical during the second quarter worth $65,000. Kovitz Investment Group Partners LLC acquired a new position in Journey Medical in the third quarter worth $66,000. ORG Wealth Partners LLC bought a new stake in Journey Medical during the third quarter valued at $110,000. Finally, Geode Capital Management LLC raised its holdings in shares of Journey Medical by 13.5% during the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock worth $613,000 after purchasing an additional 12,882 shares during the period. 7.25% of the stock is owned by institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.